The Politics of Drug Safety: An FDA Whistleblower's Push for Reform
This article was originally published in RPM Report
Executive Summary
FDA official David Graham went on Capitol Hill to discuss his view of what's wrong with the drug safety review process. He gained acclaim during the Vioxx aftermath, and proved he still has an avid following in Congress.
You may also be interested in...
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?
Running Late: FDA Review Timelines Lengthen For New Product Applications
FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result.
Running Late: FDA Review Timelines Lengthen For New Product Applications
FDA is missing more new drug review deadlines: at least seven in the first eight months of this year. The experiences of those delayed applications indicate some interesting ways to interpret what it means when a user fee date comes and goes without an FDA decision. One clear observation: the longer a sponsor has to wait after the user fee deadline, the worse the likely result.